RxDoctor Payments Data

Toni Anne de Venecia, MD

Cardiovascular Disease · Langhorne, PANPI 1801228762

Payments from drug & device makers

$3,467in general payments, 2019–2025

Across 142 payments — averaging $24.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$525
  • AstraZeneca$438
  • Merck$342
  • Amgen$315
  • Novartis$298
  • E.r. Squibb & Sons, L.L.C.$261
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$2,92084%
  • Education$54716%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,467 in reported general payments places this provider in the 60th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$146,547
Medicare patients
1,009
Services billed
1,933

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban176$187,888
EntrestoSacubitril/Valsartan62$67,991
FarxigaDapagliflozin Propanediol47$52,281
XareltoRivaroxaban31$38,183
Repatha SureclickEvolocumab33$23,252
JardianceEmpagliflozin12$16,171
Dofetilide24$12,896
Metoprolol Succinate322$5,054
Valsartan117$4,746
Atorvastatin Calcium317$3,909
Ezetimibe103$2,615
Rosuvastatin Calcium132$1,606
Bumetanide18$1,490
Eplerenone15$1,144
Midodrine Hcl17$1,120

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$222$187,888176 claims
NovartisEntresto$298$67,99162 claims
AstraZenecaFarxiga$438$52,28147 claims
Johnson & JohnsonXarelto$65$38,18331 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Langhorne

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →